Stamford, CT -- (SBWIRE) -- 02/16/2013 -- Jet Life Penny Stocks provides investors with the hot penny stock alerts on a regular basis. We will send you alerts through our Penny Stock Newsletters and offer you the tools to help you along the way with the goal of keeping you loyal to our service.
Cord Blood America Inc. (OTC:CBAI) It opened the session at $0.0029 and remained in $0.0027 and $0.003 price range during the session. The stock is -12.90 percent lowerat $0.0027. Volume closed the day at 8.68 million shares, its average volume being 9.70 million shares.
The company has total of 250 million outstanding shares and its total market capitalization is $674,998. Its beta value stands at -0.77 times and earnings per share was -$0.02.
Will CBAI Get Buyers Even After The Recent Rally? Find Out Here
CBAI was a loser in the 5 days activity and slipped about -15.62%. The one month performance of stock was negative and it plunged more than -10%.Cord Blood America, Inc., through its subsidiaries, provides private cord blood stem cell preservation services to families throughout the United States and internationally in South America, China, Germany, and Spain.
SWINGPLANE VENTURES (OTC:SWVI) traded in the range of $0.61 and $0.69 in its previous trading session. The stock recorded the volume of 8.41 million shares so far, in comparison its average daily trading volume of 10.30 million shares. The company total market capitalization is $265.35 million.
Company’s year to date performance remained quiet optimistic with the rise of 197.83%. If we look at last 6 months of trade that is in bullish zone with an increase of 356.67%.
Why Should Investors Buy SWVI After The Recent Gain? Just Go Here and Find Out
The stock opened at $0.62 and its closing price for the day was $0.685, up 12.28 percent from its previous close of $0.61. 52 week range of the stock is $0.10 -$0.69. The stock price of Swingplane Ventures continued to rally this week as more information about the potential of the Algarrobo property has been released, since our previous article. The project is advancing more quickly than expected with near-term production having been pursued more aggressively than previously indicated.
AMARANTUS BIOSCI INC (OTC:AMBS) experienced a plunge -2.26%. After opening the day at $0.08 per share, volume surged to 2.89 million, leaving behind from itsdaily average volume of 13.62 million shares. Beta value for the Company stands at -107.89, indicating its risk level. The stock remained in $0.08 and $0.08 price range during the session.
Company’s graphical value indicates these stories about the stocks: During last 5 trades the stock plummeted almost -2.03%. During last one month it slipped with the percentage of -18. Its year to date performance remained adverse with -37.88%.
Why Should Investors Buy AMBS After the Recent Fall? Just Go Here and Find Out
Stock touched its 52 week highest price point at $0.19.AmarantusBioScience, Inc., a development-stage biotechnology company, focuses on the discovery and development of therapeutic proteins and biologics for the treatment of Parkinson’s disease, traumatic brain injury (TBI), and other human diseases in the United States.
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Jet Life Penny Stocks also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)